Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Minority Interest (2016 - 2017)

IGC Pharma (IGC) has disclosed Minority Interest for 7 consecutive years, with -$9007.0 as the latest value for Q4 2017.

  • On a quarterly basis, Minority Interest changed 0.08% to -$9007.0 in Q4 2017 year-over-year; TTM through Dec 2017 was -$9007.0, a 0.08% change, with the full-year FY2017 number at -$8836.0, down 101.87% from a year prior.
  • Minority Interest was -$9007.0 for Q4 2017 at IGC Pharma, down from -$8854.0 in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $576803.0 in Q2 2014 to a low of -$9007.0 in Q4 2017.
  • A 5-year average of $393083.6 and a median of $523033.0 in 2014 define the central range for Minority Interest.
  • Peak YoY movement for Minority Interest: increased 6.96% in 2014, then plummeted 102.1% in 2017.
  • IGC Pharma's Minority Interest stood at $531772.0 in 2013, then increased by 4.67% to $556612.0 in 2014, then grew by 2.35% to $569702.0 in 2015, then crashed by 101.58% to -$9000.0 in 2016, then dropped by 0.08% to -$9007.0 in 2017.
  • Per Business Quant, the three most recent readings for IGC's Minority Interest are -$9007.0 (Q4 2017), -$8854.0 (Q3 2017), and -$8790.0 (Q2 2017).